10320 Camino Santa Fe, Suite G
San Diego, CA 92121
Tel: 858.875.1900 Fax: 858.875.1999

RARRES3 Antibody (Center)
Affinity Purified Rabbit Polyclonal Antibody (Pab)
Catalog # AP18840c

Specification

RARRES3 Antibody (Center) - Product Information

Application	**WB,E**
Primary Accession	Q9UL19
Other Accession	NP_004576.2
Reactivity	**Human**
Host	**Rabbit**
Clonality	**Polyclonal**
Isotype	**Rabbit IgG**
Calculated MW	**18179**
Antigen Region	**43-71**

RARRES3 Antibody (Center) - Additional Information

Gene ID 5920

Other Names
Retinoic acid receptor responder protein 3, 311-, HRAS-like suppressor 4, HRSL4, RAR-responsive protein TIG3, Retinoid-inducible gene 1 protein, Tazarotene-induced gene 3 protein, RARRES3, RIG1, TIG3

Target/Specificity
This RARRES3 antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 43-71 amino acids from the Central region of human RARRES3.

Dilution
WB~~1:1000
E~~Use at an assay dependent concentration.

Format
Purified polyclonal antibody supplied in PBS with 0.09% (W/V) sodium azide. This antibody is purified through a protein A column, followed by peptide affinity purification.

Storage
Maintain refrigerated at 2-8°C for up to 2 weeks. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles.

Precautions
RARRES3 Antibody (Center) is for research use only and not for use in diagnostic or therapeutic procedures.

RARRES3 Antibody (Center) - Protein Information

Name PLAAT4 (HGNC:9869)

Synonyms RARRES3, RIG1, TIG3

Function Exhibits both phospholipase A1/2 and acyltransferase activities (PubMed:19615464, PubMed:22605381, PubMed:22825852, PubMed:26503625). Shows phospholipase A1 (PLA1) and A2 (PLA2), catalyzing the calcium-independent release of fatty acids from the sn-1 or sn-2 position of glycerophospholipids (PubMed:19615464, PubMed:22605381, PubMed:22825852). For most substrates, PLA1 activity is much higher than PLA2 activity (PubMed:19615464). Shows O-acyltransferase activity, catalyzing the transfer of a fatty acyl group from glycerophospholipid to the hydroxyl group of lysophospholipid (PubMed:19615464). Shows N-acyltransferase activity, catalyzing the calcium-independent transfer of a fatty acyl group at the sn-1 position of phosphatidylcholine (PC) and other glycerophospholipids to the primary amine of phosphatidylethanolamine (PE), forming N- acylphosphatidylethanolamine (NAPE), which serves as precursor for N- acylethanolamines (NAEs) (PubMed:19615464, PubMed:22605381, PubMed:22825852). Promotes keratinocyte differentiation via activation of TGM1 (PubMed:17762858).

Cellular Location
Membrane; Single- pass membrane protein

Tissue Location
Widely expressed.

RARRES3 Antibody (Center) - Protocols

Provided below are standard protocols that you may find useful for product applications.

- Western Blot
- Blocking Peptides
- Dot Blot
- Immunohistochemistry
- Immunofluorescence
- Immunoprecipitation
- Flow Cytomety
- Cell Culture

RARRES3 Antibody (Center) - Images



RARRES3 Antibody (Center)(Cat. #AP18840c) western blot analysis in NCI-H292 cell line lysates (35ug/lane).This demonstrates the RARRES3 antibody detected the RARRES3 protein (arrow).

RARRES3 Antibody (Center) - Background

Retinoids exert biologic effects such as potent growth inhibitory and cell differentiation activities and are used in the treatment of hyperproliferative dermatological diseases. These effects are mediated by specific nuclear receptor proteins that are members of the steroid and thyroid hormone receptor superfamily of transcriptional regulators. RARRES1, RARRES2, and RARRES3 are genes whose expression is upregulated by the synthetic retinoid tazarotene. RARRES3 is thought act as a tumor suppressor or growth regulator.

RARRES3 Antibody (Center) - References

Silva, L.K., et al. Eur. J. Hum. Genet. 18(11):1221-1227(2010)
Bailey, S.D., et al. Diabetes Care 33(10):2250-2253(2010)
Uyama, T., et al. Biochim. Biophys. Acta 1791(12):1114-1124(2009)
Talmud, P.J., et al. Am. J. Hum. Genet. 85(5):628-642(2009)
Higuchi, E., et al. Oncogene 22(30):4627-4635(2003)